So the below is why this news can be considered significant and market sensitive:
This study reinforces the commercial potential and scientific credibility of MEM's RoxSta technology, which is designed to assess oxidative stress in humans and animals (oxidative stress affects reproduction as a well as a host of other human and animal medical conditions).
The study highlights RoxSta's exceptional ability to diagnose oxidative stress through rapid and precise analysis of biological fluids (i.e human and animal bodily fluids can be easily tested by RoxSta and a quick diagnosis of oxidative stress levels can be established, and hence potentially treated).
It seems that this technology has significant market value. As the below screenshot states "The global oxidative stress assay market size was estimated at USD 1.12 billion in 2023 and is projected to grow at a CAGR of 9.43% from 2024 to 2030"
Basically, the study helps to confirm the effectiveness and importance of RoxSta technology, and hence confirms its commercial value in a multi-billion dollar market.
MEM Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)